GRACEcastUC 126 Lung_Is it possible to Test for Biomarkers on a National Scale?

(5:16)

GRACEcastUC 127 Lung_Molecular Markers Predicting the Best Chemotherapy to use in Lung Cancer

(5:39)

GRACEcast-126_Rad_Refining Radiation Therapy for Lung Cancer, Part 6: Metastatic Lung Cancer

(5:51)

GRACEcastUC-002 - How Should We Treat Locally Advanced Non-Small Cell Lung Cancer?

(4:20)

GRACEcastUC-007 - Is there an alternative to radiation for patients with several brain metastases?

(5:35)

How do we approach acquired resistance to targeted therapies in lung cancer?

(5:51)

Can we target KRAS effectively in advanced NSCLC?

(4:4)

Can a \

(6:10)

Could BRAF be a new target in NSCLC?

(4:57)

Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC

(12:50)

Do you need Avastin in first line and maintenance therapy in advanced NSCLC?

(6:37)

Psalm 126 Sermon, \

(36:21)

Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement

(6:49)

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

(2:26)

GRACEcast-088_Lung-Cancer_Challenging Cases in Lung Cancer: Acquired Resistance to EGFR TKI Therapy

(28:22)

Kidney Cancer Immunotherapy: Reasons for Cautious Optimism

(18:46)

GRACEcast-125_Rad_Refining Radiation Therapy for Lung Cancer, Part 5: New Techniques

(10:57)